Opendata, web and dolomites


Diabeloop to Patients: An Artificial Pancreas solution to improve the balance, safety and autonomy of 20 million people

Total Cost €


EC-Contrib. €






 D2P project word cloud

Explore the words cloud of the D2P project. It provides you a very rough idea of what is the project "D2P" about.

netherlands    innovation    diseases    components    regulation    sweden    diabetes    20    daily    identification    specificities    loop    intelligence    autoimmune    situations    patient    optimisation    industrialisation    death    begin    calculate    handset    market    closed    pump    coma    alleviate    monitoring    million    exchange    function    secured    heart    sensor    telemedicine    periods    continuous    fainting    dose    storage    t1d    validate    mimic    patients    glucose    diabeloop    france    regulating    made    anyone    solution    hypoglycaemia    countries    basis    cells    physiological    dblg1    breakthrough    foreign    pancreas    day    models    burden    seizures    artificial    beta    generation    first    adoption    data    insulin    treatment    telemonitoring    half    people    algorithms    complications    stressful    reduce    model    device    integrates    personalised    blindness    countless    destruction    goals    hyperglycaemia    hosting    suggest    healthy    renal    producing    worldwide    adjustments    healthcare    amputations    performances    complementary    automatically    customisation    core    delivered    appropriate    professional    clinicians    connected    upgrade    severe    causes    age   

Project "D2P" data sheet

The following table provides information about the project.


Organization address
address: 155-157 COURS BERRIAT
postcode: 38028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙190 €
 EC max contribution 1˙955˙233 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DIABELOOP FR (GRENOBLE) coordinator 1˙955˙233.00


 Project objective

20 million people worldwide are affected by type 1 diabetes (T1D), an autoimmune condition leading to the destruction of beta cells of the pancreas producing insulin. T1D causes severe complications: short terms - seizures and fainting that could result in coma or even death; long terms - blindness, amputations, renal failure, heart diseases. T1D can occur to anyone and half of the cases begin before age 20. T1D patients have to manage their diabetes on a daily basis, facing countless stressful situations.

Diabeloop’s “artificial pancreas” solution aims to mimic the glucose regulating function of a healthy pancreas. The core of our “artificial pancreas” solution is an artificial intelligence: algorithms based on physiological models continuously calculate the most appropriate and personalised dose of insulin. Insulin is then automatically delivered to the patient. Diabeloop goals are to reduce hypoglycaemia and hyperglycaemia periods, alleviate the day-to-day burden and avoid long-term complications.

Diabeloop’s first generation solution (DBLG1) is integrated in a closed-loop system made of three components: a continuous glucose monitoring sensor, a connected insulin pump, and a handset hosting algorithms and controlling the pump. Diabeloop’s solution integrates a telemedicine program through highly secured data exchange, storage and healthcare professional identification. Clinicians may access the patients’ data and suggest treatment adjustments as necessary, for an improved system customisation and long-term regulation. During the phase 2 project, we scale up and target a European adoption of our breakthrough innovation. We focus on France, the Netherlands and Sweden, 3 countries with complementary specificities to validate our model: adaptation of the device to foreign market, optimisation of performances, telemonitoring upgrade and industrialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "D2P" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "D2P" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More